AAMIR ZAMAN
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology CLIFTON, NJ NPI 1659542702
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology NJ Acerta Pharma LLC All categories
General Payments — all program years on this page
$3,033.82
- Category: General Payments
- Program years: PY2018–2024
- Record count: 135
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $739.26 across 34 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $721.04 | 33 |
| Education | $18.22 | 1 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Acerta Pharma LLC | $160.57 | 4 |
| Merck Sharp & Dohme Corporation | $38.95 | 2 |
| GlaxoSmithKline, LLC. | $38.58 | 2 |
| Adaptive Biotechnologies Corporation | $34.12 | 1 |
| Janssen Biotech, Inc. | $33.38 | 2 |
| Mirati Therapeutics, Inc. | $29.79 | 1 |
| Pharmacosmos Therapeutics Inc. | $23.24 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $22.97 | 1 |
| Dendreon Pharmaceuticals LLC | $22.22 | 1 |
| Apellis Pharmaceuticals, Inc. | $21.99 | 1 |
| BeiGene USA, Inc. | $21.19 | 1 |
| Astellas Pharma US Inc | $21.05 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $20.00 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $18.59 | 1 |
| Regeneron Healthcare Solutions, Inc. | $18.35 | 1 |
| Lilly USA, LLC | $17.68 | 1 |
| Blueprint Medicines Corporation | $17.53 | 1 |
| Azurity Pharmaceuticals, Inc. | $17.48 | 1 |
| Stemline Therapeutics Inc. | $17.13 | 1 |
| Ipsen Biopharmaceuticals, Inc | $17.00 | 1 |
| Daiichi Sankyo Inc. | $17.00 | 1 |
| Gilead Sciences, Inc. | $16.69 | 1 |
| Octapharma USA, Inc. | $16.67 | 1 |
| Incyte Corporation | $16.52 | 1 |
| JAZZ PHARMACEUTICALS INC. | $16.33 | 1 |
| PFIZER INC. | $15.26 | 1 |
| E.R. Squibb & Sons, L.L.C. | $14.69 | 1 |
| Alnylam Pharmaceuticals Inc. | $14.29 | 1 |
By program year
Records — PY2024 (34)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.